Personalized melanoma vaccine cuts recurrence risk 42% in trial

Researchers report a personalized mRNA vaccine targeting melanoma reduced recurrence risk by 42% in a clinical trial, building on two decades of Australian-led cancer vaccine research. The finding is preliminary and not yet peer-reviewed in full, but it represents a notable step in individualized immunotherapy. If confirmed, it could shift adjuvant treatment paradigms for high-risk melanoma.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works